Clearsight and Covalent Medical have signed an LOI for $63M over 5years. ClearSight will manufacture and produce 6 unique SKUs for Covalent Medical to commercialize and sell. The agreement will entail 3 products under the Focus Tears brand family (www.focusvitamins.com), which will be sold directly through Ophthalmologists and Optometrists to patients suffering from Dry Eye, Wearing contact lenses and Pink Eye. They will also launch 3 SKUs under a separate brand, Alivyo, for sale through the Retail Channel (CVS, Walgreens, etc.).

ClearSight will manufacture and provide a private-label version of our innovative over-the-counter (OTC) pink eye treatment. Cartwheel will package and sell this product to major retail chains in the US under its brand. Cartwheel is set to launch its lice treatment in 2026 and will focus on introducing the ClearSight formulation in 2027.

We have finished developing our formulation and conducted pre-clinical tests for antibacterial, antifungal, and antiviral activity. We have also started our key pre-clinical biofilm study and expect to see results soon.

Established a partnership with Unither Pharma, Rochester, NY, for the development and manufacturing of our clinical and commercial products.

Established a partnership with Chitolytic to supply ClearSight with GMP-quality active pharmaceutical ingredient (API) which is a critical component of our novel ophthalmic solutions.